Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models
- 31 March 2023
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 378, 110467
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Science and Technology Development Foundation
- Universidade de Macau (MYRG2019-00034-FHS)
- Universidade de Macau (HEK293)
This publication has 59 references indexed in Scilit:
- A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescenceNature, 2013
- ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effectNature Cell Biology, 2012
- Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic targetInternational Journal of Oncology, 2012
- Deconvoluting the context-dependent role for autophagy in cancerNature Reviews Cancer, 2012
- Overexpression of Pyruvate Dehydrogenase Kinase 3 Increases Drug Resistance and Early Recurrence in Colon CancerThe American Journal of Pathology, 2011
- Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomasCancer, 2008
- Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancerBritish Journal of Cancer, 2008
- Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer CellsJournal of Biological Chemistry, 2008
- Recognition of the Inner Lipoyl-Bearing Domain of Dihydrolipoyl Transacetylase and of the Blood Glucose-Lowering Compound AZD7545 by Pyruvate Dehydrogenase Kinase 2Biochemistry, 2007
- AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3Biochemical Pharmacology, 2006